
|Videos|January 27, 2022
Trends in the ASCVD, LDL-C Management Treatment Landscape in 2022
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the interview, Lepor discussed some of the major trends in the ASCVD and LDL-C management treatment landscape this year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials
2
FDA Adds a New Sunscreen to the OTC Repertoire
3
Drug Shortages Are Declining, But Persistent Supply Chain Vulnerabilities Continue to Threaten Access
4
Tec-Dara: Match Made in Heaven or Double Trouble?
5



















































































































